Scholarlink

Background and aims <p>Cisplatin is one of effect chemotherapeutic drugs for triple-negative breast cancer (TNBC). However, cisplatin chemoresistance often generate in a notable proportion of TNBC patients, leading therapeutic failure. Thus, identification of key regulatory mechanisms for chemoresistance is important. Here, we aimed to study the functions and regulatory mechanisms of CLEC3B in cisplatin chemoresistance in TNBC.</p> Methods <p>MTT assay, colony formation assay and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay were employed to investigate the role of CLEC3B in cisplatin (CDDP) resistance in TNBC. Fe2<sup>+</sup> Current assay and MDA level assay were used to determine CLEC3B’s role in ferroptosis. Co-Immunoprecipitation was used to determine the interaction proteins of CLEC3B. Western blotting assay were performed to determine CLEC3B’s role in solute carrier family 39 member 8 (SLC39A8) and solute carrier family 39 member 14 (SLC39A14) levels.</p> Results <p>Here, we find that CLEC3B was downregulated in TNBC tissues, especially in relapsed TNBC tissues. TNBC patients with high CLEC3B levels had better prognosis than those with low CLEC3B levels after chemotherapy. Functional assays showed that CLEC3B promoted CDDP chemosensitivity. Mechanistic assays found that CLEC3B promoted CDDP chemosensitivity via inducing ferroptosis. Moreover, CLEC3B interacted with SLC39A8 and&#xa0;SLC39A14 and knockdown of them reversed the effect of CLEC3B overexpression on chemosensitivity.</p> Conclusions <p>In summary, CLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

C-type lectin domain family 3 member B (CLEC3B) inhibits triple-negative breast cancer chemoresistance via inducing ferroptosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月6日

查看全文
  • Lina Peng,
  • Wenhui Yan,
  • Juanjuan Mei,
  • Hongbo Lan,
  • Fei Chen,
  • Kun Xie,
  • Jingshuang Wang,
  • Futing Mu,
  • Xunpeng Luo,
  • Yanan Liu

摘要

Background and aims

Cisplatin is one of effect chemotherapeutic drugs for triple-negative breast cancer (TNBC). However, cisplatin chemoresistance often generate in a notable proportion of TNBC patients, leading therapeutic failure. Thus, identification of key regulatory mechanisms for chemoresistance is important. Here, we aimed to study the functions and regulatory mechanisms of CLEC3B in cisplatin chemoresistance in TNBC.

Methods

MTT assay, colony formation assay and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay were employed to investigate the role of CLEC3B in cisplatin (CDDP) resistance in TNBC. Fe2+ Current assay and MDA level assay were used to determine CLEC3B’s role in ferroptosis. Co-Immunoprecipitation was used to determine the interaction proteins of CLEC3B. Western blotting assay were performed to determine CLEC3B’s role in solute carrier family 39 member 8 (SLC39A8) and solute carrier family 39 member 14 (SLC39A14) levels.

Results

Here, we find that CLEC3B was downregulated in TNBC tissues, especially in relapsed TNBC tissues. TNBC patients with high CLEC3B levels had better prognosis than those with low CLEC3B levels after chemotherapy. Functional assays showed that CLEC3B promoted CDDP chemosensitivity. Mechanistic assays found that CLEC3B promoted CDDP chemosensitivity via inducing ferroptosis. Moreover, CLEC3B interacted with SLC39A8 and SLC39A14 and knockdown of them reversed the effect of CLEC3B overexpression on chemosensitivity.

Conclusions

In summary, CLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.